{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:02:56Z","timestamp":1789614176765,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009030","name":"Strategic Promotion of Innovative R and D","doi-asserted-by":"publisher","award":["JPJ012425"],"award-info":[{"award-number":["JPJ012425"]}],"id":[{"id":"10.13039\/501100009030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cilostazol has antiplatelet and vasodilatory properties and may provide renoprotective and cardiovascular benefits; however, its effects in patients with advanced chronic kidney disease (CKD) remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective pilot study enrolled 12 patients with advanced CKD due to nephrosclerosis (7 men, 5 women; mean age 65.3\u2009\u00b1\u200911.0\u00a0years). Patients were randomly assigned to receive cilostazol 200\u00a0mg\/day plus aspirin 100\u00a0mg\/day (Group C, n\u2009=\u20096) or aspirin 100\u00a0mg\/day alone (Group A, n\u2009=\u20096). Glomerular filtration rate (GFR) and renal plasma flow (RPF) were measured using inulin and para-aminohippuric acid clearance at baseline and after 1\u00a0year. Renal outcomes and complications were evaluated, followed by long-term observation until initiation of renal replacement therapy (RRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline GFR and RPF were comparable between groups. After 1\u00a0year, GFR increased in 4 of 6 patients in Group C but declined in all patients in Group A. Mean GFR decreased significantly in Group A but not in Group C. Although estimated GFR declined in both groups, the annual rate of decline was significantly slower in Group C than in Group A (\u2212\u20092.72 vs.\u2009\u2212\u20093.84\u00a0mL\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      \/year). RPF and urinary protein levels showed no significant changes in either group. Over a mean follow-up of 6.7\u00a0years, RRT was initiated in 2 patients in Group C and 4 in Group A. Two cerebral infarctions occurred in Group A, whereas no cardiovascular events occurred in Group C.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cilostazol may slow short-term renal function decline and offer long-term cardiovascular protection in patients with advanced CKD. Further studies are needed to determine its role in preventing long-term renal deterioration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02897-8","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:40:54Z","timestamp":1780890054000},"page":"1426-1432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of cilostazol on renal function, renal blood flow, and long-term prognosis in patients with chronic kidney disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Chie","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Mase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoya","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Simizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Morito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirayasu","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joichi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7407-0410","authenticated-orcid":false,"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"2897_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1161\/01.STR.0000149621.95215.ea","volume":"36","author":"J Leonardi-Bee","year":"2005","unstructured":"Leonardi-Bee J, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36(1):162\u20138.","journal-title":"Stroke"},{"issue":"3","key":"2897_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jcph.1988","volume":"62","author":"AA Manolis","year":"2022","unstructured":"Manolis AA, et al. Update on cilostazol: a critical review of its antithrombotic and cardiovascular actions and its clinical applications. J Clin Pharmacol. 2022;62(3):320\u201358.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2897_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137\u201347.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2897_CR4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-013-0002-3","volume":"45","author":"WH Tang","year":"2014","unstructured":"Tang WH, et al. Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. Endocrine. 2014;45(2):293\u2013301.","journal-title":"Endocrine"},{"key":"2897_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000401438","volume":"9","author":"S Tojo","year":"1978","unstructured":"Tojo S, et al. Dipyridamole therapy in the nephrotic syndrome. Contrib Nephrol. 1978;9:111\u201327.","journal-title":"Contrib Nephrol"},{"issue":"4","key":"2897_CR6","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.18632\/oncotarget.19850","volume":"9","author":"KL Kuo","year":"2018","unstructured":"Kuo KL, et al. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. Oncotarget. 2018;9(4):5368\u201377.","journal-title":"Oncotarget"},{"issue":"6","key":"2897_CR7","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392.","journal-title":"Am J Kidney Dis"},{"issue":"10225","key":"2897_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"G.B.D.C.K.D. Collaboration","year":"2020","unstructured":"G.B.D.C.K.D. Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"4","key":"2897_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2215\/CJN.07830520","volume":"16","author":"M Hannan","year":"2021","unstructured":"Hannan M, et al. Risk factors for CKD progression: overview of findings from the CRIC study. Clin J Am Soc Nephrol. 2021;16(4):648\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"2897_CR10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861\u20139.","journal-title":"N Engl J Med"},{"issue":"15","key":"2897_CR11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"6","key":"2897_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal R, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533\u201343.","journal-title":"N Engl J Med"},{"issue":"23","key":"2897_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, et al. Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"2897_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","volume":"13","author":"SV Badve","year":"2025","unstructured":"Badve SV, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2897_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119843","volume":"282","author":"K Thapa","year":"2021","unstructured":"Thapa K, Singh TG, Kaur A. Cyclic nucleotide phosphodiesterase inhibition as a potential therapeutic target in renal ischemia reperfusion injury. Life Sci. 2021;282:119843.","journal-title":"Life Sci"},{"key":"2897_CR16","doi-asserted-by":"publisher","first-page":"8236903","DOI":"10.1155\/2016\/8236903","volume":"2016","author":"PS Lim","year":"2016","unstructured":"Lim PS, et al. Role of cilostazol therapy in hemodialysis patients with asymptomatic peripheral arterial disease: a retrospective cohort study. Biomed Res Int. 2016;2016:8236903.","journal-title":"Biomed Res Int"},{"key":"2897_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123661","volume":"477","author":"J Koge","year":"2025","unstructured":"Koge J, et al. Effect of renal function on dual antiplatelet therapy using cilostazol for stroke prevention: A CSPS.com trial post hoc analysis. J Neurol Sci. 2025;477:123661.","journal-title":"J Neurol Sci"},{"key":"2897_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1283385","volume":"10","author":"JL Lu","year":"2023","unstructured":"Lu JL, et al. Association of long-term aspirin use with kidney disease progression. Front Med Lausanne. 2023;10:1283385.","journal-title":"Front Med Lausanne"},{"key":"2897_CR19","doi-asserted-by":"publisher","DOI":"10.34172\/jrip.2024.37317","author":"R Eskandarian","year":"2024","unstructured":"Eskandarian R, Pari SM, Memarian M. Examining the impact of aspirin on patients with chronic kidney disease; a systematic review and meta-analysis. J Ren Inj Prev. 2024. https:\/\/doi.org\/10.34172\/jrip.2024.37317.","journal-title":"J Ren Inj Prev"},{"issue":"1","key":"2897_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40360-024-00771-5","volume":"25","author":"S Bonet-Monne","year":"2024","unstructured":"Bonet-Monne S, et al. NSAIDs, analgesics, antiplatelet drugs, and decline in renal function: a retrospective case-control study with SIDIAP database. BMC Pharmacol Toxicol. 2024;25(1):58.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"7","key":"2897_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1271\/bbb.90938","volume":"74","author":"WC Lee","year":"2010","unstructured":"Lee WC, et al. Cilostazol ameliorates nephropathy in type 1 diabetic rats involving improvement in oxidative stress and regulation of TGF-Beta and NF-kappaB. Biosci Biotechnol Biochem. 2010;74(7):1355\u201361.","journal-title":"Biosci Biotechnol Biochem"},{"issue":"4","key":"2897_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10557-021-07187-x","volume":"36","author":"RY Kherallah","year":"2022","unstructured":"Kherallah RY, et al. Cilostazol: a review of basic mechanisms and clinical uses. Cardiovasc Drugs Ther. 2022;36(4):777\u201392.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"8","key":"2897_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.5551\/jat.63404","volume":"30","author":"CK Wu","year":"2023","unstructured":"Wu CK, et al. Long-term effectiveness of Cilostazol in patients with hemodialysis with peripheral artery disease. J Atheroscler Thromb. 2023;30(8):943\u201355.","journal-title":"J Atheroscler Thromb"},{"issue":"7","key":"2897_CR24","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","volume":"30","author":"HM Colhoun","year":"2024","unstructured":"Colhoun HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058\u201366.","journal-title":"Nat Med"},{"issue":"7","key":"2897_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1159\/000524890","volume":"53","author":"GL Bakris","year":"2022","unstructured":"Bakris GL, Weir MR. Initial drops in glomerular filtration rate with certain drug classes retard kidney disease progression. Am J Nephrol. 2022;53(7):513\u20135.","journal-title":"Am J Nephrol"},{"issue":"12","key":"2897_CR26","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s10157-024-02532-4","volume":"28","author":"R Kawano","year":"2024","unstructured":"Kawano R, et al. Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip. Clin Exp Nephrol. 2024;28(12):1282\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"2897_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j791","volume":"356","author":"M Schmidt","year":"2017","unstructured":"Schmidt M, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791.","journal-title":"BMJ"},{"issue":"7","key":"2897_CR28","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/dom.15611","volume":"26","author":"T Kanaoka","year":"2024","unstructured":"Kanaoka T, et al. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database. Diabetes Obes Metab. 2024;26(7):2905\u201314.","journal-title":"Diabetes Obes Metab"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02897-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02897-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:51:21Z","timestamp":1789613481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02897-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2897"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02897-8","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kunihiro Yamagata has received research grant from Otsuka Pharmaceutical co.. Chie Saito, Kaori Mase, Takuya Harada, Shun Ishibashi, Ryoya Tsunoda, Toshiaki Usui, Tatsuya Simizu, Kei Nagai, Reiko Ohkubo, Naoki Morito, Masahiro Hagiwara, Hirayasu Kai, Joichi Usui have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee of Tsukuba University at which the studies were conducted (IRB approval number H18-68) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","label":"Human and animal rights","group":{"name":"EthicsHeading","label":"Declarations"}}]}}